Skip to main navigation
Skip to search
Skip to main content
Augusta University Research Profiles Home
Help & FAQ
Home
Profiles
Research units
Equipment
Grants
Scholarly Output
Datasets
Activities
Prizes
Search by expertise, name or affiliation
HER2 and breast cancer stem cells: More than meets the eye
Hasan Korkaya, Max S. Wicha
Research output
:
Contribution to journal
›
Review article
›
peer-review
98
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'HER2 and breast cancer stem cells: More than meets the eye'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Adjuvant Therapy
25%
Adjuvant Trastuzumab
25%
Breast Cancer
25%
Breast Cancer Stem Cells
100%
Breast Cancer Treatment
25%
Cancer Stem Cells
50%
Clinical Benefit
25%
Clinical Efficacy
25%
Clinical Trials
25%
HER2 Amplification
25%
HER2-positive
50%
HER2-positive Breast Cancer
25%
HER2-targeted Therapy
25%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Molecular Targeted Therapy
25%
Mouse Model
25%
Natural History
25%
Neoadjuvant Setting
25%
Retrospective Analysis
25%
Stem Cell Population
75%
Trastuzumab
25%
Tumor
75%
Tumor Microenvironment
25%
Tumor Subtype
25%
Medicine and Dentistry
Adjuvant Therapy
25%
Biological Product
25%
Breast Cancer
100%
Cancer Stem Cell
100%
Cancer Therapy
25%
Cell Population
75%
Clinical Trial
25%
Gene Amplification
25%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
25%
Molecularly Targeted Therapy
25%
Neoplasm
100%
Trastuzumab
50%
Tumor Microenvironment
25%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Product
25%
Breast Cancer
100%
Clinical Trial
25%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
25%
Malignant Neoplasm
50%
Mouse Model
25%
Neoplasm
100%
Trastuzumab
50%
Tumor Microenvironment
25%
Immunology and Microbiology
Biological Product
25%
Cancer Stem Cell
100%
Cell Population
75%
Gene Amplification
25%
Mouse Model
25%
Trastuzumab
50%
Biochemistry, Genetics and Molecular Biology
Cancer Stem Cell
100%
Clinical Trial
25%
Gene Amplification
25%
Mouse Model
25%
Trastuzumab
50%
Neuroscience
Adjuvant Therapy
25%
Cancer Stem Cell
100%
Gene Amplification
25%
Trastuzumab
50%